- Home
- BOW vs PHVS Comparison
BOW vs PHVS Comparison
Compare BOW & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- PHVS
- Stock Information
- Founded
- BOW 2020
- PHVS 2015
- Country
- BOW United States
- PHVS Switzerland
- Employees
- BOW N/A
- PHVS N/A
- Industry
- BOW Property-Casualty Insurers
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- PHVS Health Care
- Exchange
- BOW Nasdaq
- PHVS Nasdaq
- Market Cap
- BOW 1.2B
- PHVS 980.9M
- IPO Year
- BOW 2024
- PHVS 2021
- Fundamental
- Price
- BOW $33.22
- PHVS $22.32
- Analyst Decision
- BOW Buy
- PHVS Buy
- Analyst Count
- BOW 6
- PHVS 6
- Target Price
- BOW $39.67
- PHVS $37.17
- AVG Volume (30 Days)
- BOW 235.2K
- PHVS 33.8K
- Earning Date
- BOW 08-05-2025
- PHVS 08-13-2025
- Dividend Yield
- BOW N/A
- PHVS N/A
- EPS Growth
- BOW 18.99
- PHVS N/A
- EPS
- BOW 1.33
- PHVS N/A
- Revenue
- BOW $457,704,000.00
- PHVS N/A
- Revenue This Year
- BOW $22.94
- PHVS N/A
- Revenue Next Year
- BOW $20.42
- PHVS N/A
- P/E Ratio
- BOW $24.95
- PHVS N/A
- Revenue Growth
- BOW 45.29
- PHVS N/A
- 52 Week Low
- BOW $24.80
- PHVS $11.51
- 52 Week High
- BOW $42.29
- PHVS $25.76
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- PHVS 73.31
- Support Level
- BOW N/A
- PHVS $17.63
- Resistance Level
- BOW N/A
- PHVS $19.00
- Average True Range (ATR)
- BOW 0.00
- PHVS 1.20
- MACD
- BOW 0.00
- PHVS 0.35
- Stochastic Oscillator
- BOW 0.00
- PHVS 92.15
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.